Toronto Replication of the Saskatchewan LSD Treatment Trial

The Toronto Replication of the Saskatchewan LSD Treatment Trial was an early-1960s effort to test whether the celebrated results of LSD treatment for alcohol dependence in Saskatchewan could withstand stricter controls. The trial did not reproduce those results: some participants underwent frightening sessions in a deliberately impersonal setting. The disagreement that followed exposed a central problem in evaluating psychedelic therapy—whether isolating the drug from its surroundings clarifies its effects, or removes conditions on which those effects depend.

Background: Saskatchewan’s Promising Results

At Weyburn hospital, Humphry Osmond and Abram Hoffer had treated people with alcohol dependence using LSD. Their results appeared so promising that, by the end of the 1950s, LSD was widely regarded in North America as a potential miracle treatment for alcoholism. The Saskatchewan provincial government helped make LSD therapy a standard treatment option for alcoholics in the province. But the strength of the claims also invited skepticism: to critics in the Canadian medical establishment, the results seemed too good to be true.

The treatment’s emerging rationale had already begun to move beyond the idea that LSD merely produced temporary psychosis. Osmond and Hoffer heard reports of experiences that seemed to participants more like spiritual insight or transcendence. They also found that the circumstances of a session mattered: an engaged, empathetic therapist could help prevent a bad experience, while an impersonal clinical atmosphere might contribute to distress. The Toronto replication therefore tested Saskatchewan’s claims in a context where the therapeutic relationship and the room itself would become part of the controversy.

The Toronto Experiment

The Addiction Research Foundation in Toronto, then Canada’s leading institute of its kind, set out to replicate the Saskatchewan trials with what it considered better controls. Its clinicians hoped to distinguish the effects of LSD from other influences. Alcoholic volunteers received the drug in neutral rooms and were instructed to avoid engaging with them during their sessions, apart from administering an extensive questionnaire.

The conditions were not simply quiet or minimally social. Volunteers were also restrained or blindfolded, and some experienced both. These procedures made the sessions sharply different from the more engaged treatment approach associated with Osmond and Hoffer. Instead of a therapist’s supportive presence, participants encountered an environment organized around neutrality, observation, and measurement. The design sought to control variables, but the experience it created could itself shape what happened.

Results and Dispute over Interpretation

The Toronto results failed to match the outcomes reported in Saskatchewan. More than a few participants endured terrifying experiences, later commonly called bad trips. Critics of LSD treatment for alcoholism took the replication to show that the treatment performed poorly under rigorous control. Supporters drew a different lesson: if the results depended on the therapist’s presence and the session’s atmosphere, then attention to set and setting was essential to the treatment’s success.

Both interpretations captured part of the evidence. The Toronto study did not confirm the earlier claims under its controlled conditions; at the same time, those conditions differed in consequential ways from the therapeutic environment credited with the Saskatchewan results. The trial therefore could not settle the question simply by producing a less favorable outcome. It also raised a methodological question: when a treatment includes interpersonal care and a carefully prepared setting, should those elements be treated as confounding influences to remove, or as components whose contribution must be studied?

Significance: What Counts as a Controlled Test

The replication became an example of the tension between experimental control and the practical form of psychedelic therapy. A neutral room and restricted interaction might help isolate a drug’s pharmacological effects, but they could also create the very conditions associated with distress. The contrast anticipates a broader debate about the role of the therapist, the patient’s expectations, and the environment in psychedelic treatment.

That debate also reflected a clash between models of what the drugs did. Psychotomimetic explanations could fit the effects within familiar psychiatric categories, while psychedelic therapy proposed a high-dose session aimed at a profound, potentially transformative experience. This approach challenged conventional professional boundaries between medicine and spirituality, and sat uneasily with the rising status of the double-blind, placebo-controlled trial as the standard for evaluating drugs. The Toronto replication thus mattered both as an attempted test of Saskatchewan’s results and as a demonstration that experimental design could not be separated from the question of what, exactly, the therapy was.